SOPHiA GENETICS SA (SOPH)

SOPHiA GENETICS SA (SOPH) is a healthcare company (health information services) based in Switzerland. The share price is $7.32, down 1.61% on the day, which values the company at $627.02M. Price as of 17 Nov 2026, 17:43 UTC, from Yahoo Finance.

Key facts

Share price
$7.32−1.61% today
Market value
$627.02M
Funk Score
36/100
Against its own history
Well above its usual priceusual price $2.77
200-week average
$4.3767% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

SOPHiA GENETICS SA in more detail

SOPH trades at -13.3× next year's expected earnings, 6.9× sales. Measured against its own history, the price is 164% above what its usual multiples would imply ($2.77) — well above its usual price. It sits 67% above its 200-week average of $4.37.

Its Funk Score is 36 out of 100 (financial strength 2.9, profitability 2.0, growth 9.5, value 0.0, each out of 10).

In its favour: Operating margin is expanding; More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

2 of the superinvestors tracked here hold SOPH, including Chuck Akre (0.7% of the portfolio), Chuck Royce (founder) (0.3% of the portfolio).

Superinvestors holding SOPH

2 of the investors tracked here report a position in their latest 13F filing.

SOPHiA GENETICS SA (SOPH): questions and answers

What is SOPHiA GENETICS SA's market cap?

SOPHiA GENETICS SA is valued at $627.02M at a share price of $7.32.

Is SOPH overvalued or undervalued?

Against its own history, SOPH is well above its usual price: the price is 164% above the $2.77 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is SOPH above its 200-week moving average?

Yes. SOPH is 67.5% above its 200-week average of $4.37. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is SOPHiA GENETICS SA growing?

Over the last three fiscal years SOPHiA GENETICS SA's revenue grew 17.6% a year.

Does SOPH pay a dividend?

SOPHiA GENETICS SA does not currently pay a regular dividend.

Which famous investors own SOPH?

In their latest quarterly filings, Chuck Akre (0.7% of the portfolio), Chuck Royce (founder) (0.3% of the portfolio) hold SOPH. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “SOPHiA GENETICS SA (SOPH) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/SOPH

Underlying data: Yahoo Finance; company filings with the SEC.